These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34864786)

  • 1. Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation.
    Brogdon H; Facer KL; Cox EJ; Carlson RH; Wurzel JF
    J Addict Med; 2022 Jul-Aug 01; 16(4):488-491. PubMed ID: 34864786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
    Ward HB; Barnett BS; Suzuki J
    Subst Abus; 2019; 40(2):140-145. PubMed ID: 30888254
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
    Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
    Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
    Azar P; Nikoo M; Miles I
    Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
    Bhatraju EP; Klein JW; Hall AN; Chen DR; Iles-Shih M; Tsui JI; Merrill JO
    J Addict Med; 2022 Jul-Aug 01; 16(4):461-465. PubMed ID: 34954743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.
    Terasaki D; Smith C; Calcaterra SL
    Pharmacotherapy; 2019 Oct; 39(10):1023-1029. PubMed ID: 31348544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic.
    Shahlapour M; Singh S; Christine PJ; Laks J; Evans J; Farrell NM; Khan GK; Taylor JL; Rozansky H
    J Addict Med; 2024 May-Jun 01; 18(3):345-347. PubMed ID: 38329815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.
    Baker JR; Best AM; Pade PA; McCance-Katz EF
    Ann Pharmacother; 2006 Mar; 40(3):392-6. PubMed ID: 16507617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up.
    Fareed A; Patil D; Scheinberg K; Blackinton Gale R; Vayalapalli S; Casarella J; Drexler K
    J Addict Dis; 2013; 32(3):244-51. PubMed ID: 24074190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
    Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
    Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
    Antoine D; Huhn AS; Strain EC; Turner G; Jardot J; Hammond AS; Dunn KE
    Am J Addict; 2021 Jan; 30(1):83-87. PubMed ID: 32572978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
    Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
    Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
    Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
    Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
    Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
    J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.